MORE►
pharmaceuticals
Dr. Deborah Dunsire recently retired as president and CEO of H. Lundbeck A/S, a biopharmaceutical company focused on brain disease therapies. [Image: photo, Business Wire; background DI Studio]
Irving’s McKesson Corp. Adds Healthcare Veteran to Board
by Lance Murray | Jun 7, 2024
Dr. Deborah Dunsire joins the board with more than 30 years of experience leading large, matrixed organizations in the biopharmaceutical, oncology, and other specialty industries, including her role as president and CEO of H. Lundbeck A/S.
by Lance Murray |
Jun 17, 2023
Dallas-based SpotSee announced that it acquired unique temperature indicator technologies and intellectual property from Sensor International in May. SpotSee is a global leader in environmental condition monitoring solutions, and the deal represented SpotSee’s second acquisition within two weeks....
MORE►
by Quincy Preston |
Aug 17, 2022
The University of North Texas BioDiscovery Institute's $1.4 million grant from the W. M. Keck Foundation is seeding research in sustainable medicine—literally.
“What we're thinking long-term is that if plants can store medicines in seeds, you eat the seeds, and the medicine is already contained. You don't have all these factories, you don't need any chemicals—it's just there and available,” said UNT lead researcher Elizabeth Skellam.
“What we're thinking long-term is that if plants can store medicines in seeds, you eat the seeds, and the medicine is already contained. You don't have all these factories, you don't need any chemicals—it's just there and available,” said UNT lead researcher Elizabeth Skellam.
MORE►
by Kevin Cummings |
Feb 16, 2022
Renibus Therapeutics, which focuses on treatments for acute and chronic kidney diseases, announced closing a $35 million Series A funding round. Its new CEO, Frank Stonebanks, says "Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases."
MORE►
Marketing image for one of Eyevance Pharmaceuticals' products, Flarex. [eyevance.com]
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by Alex Edwards | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
by Quincy Preston |
Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
by Lance Murray |
Sep 9, 2019
Among the contributions of recipient Paul Dorman, the chairman and CEO of DFB Pharmaceuticals, is paying for the first-year tuition of the entire inaugural class of M.D. students at the TCU and UNTHSC School of Medicine in Fort Worth.
MORE►
